BETHESDA, Md., Sept. 27, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") today announced the poster presentation of data evaluating the long-term safety of AMITIZA ® (lubiprostone) as a treatment for adults with chronic, non-cancer pain suffering from opioid-induced constipation (OIC). This poster presentation demonstrates that AMITIZA does not affect opioid-induced analgesia, was well-tolerated, and resulted in overall improvement in symptoms in OIC patients. Sucampo will present this data at the 24 th Annual Clinical Meeting for the American Academy of Pain Management (AAPM) in Orlando, Florida on Friday, September 27, 2013.
- Lubiprostone Does not Affect Analgesia in OIC Patients
Additional information about the AAPM's 24th Annual Clinical Meeting can be found at http://www.aapainmanage.org/conference/annual-clinical-meeting/ . About AMITIZA AMITIZA (lubiprostone) capsules are indicated for the treatment of chronic idiopathic constipation (CIC) in adults and OIC in adults with chronic, non-cancer pain (24 mcg twice daily). The effectiveness in patients with OIC taking diphenylheptane opioids (e.g., methadone) has not been established. AMITIZA is also indicated for irritable bowel syndrome with constipation (IBS-C) in women > 18 years old (8 mcg twice daily).
- Taryn Joswick, BS, PMP, Egilius L. H. Spierings, MD, PhD, Elizabeth Linder, Ryuji Ueno, MD, PhD, PhD, Poster 18